A more recent study for patients with relapsed or refractory MCL who progressed on BTK inhibition in the pre-CAR T-cell era is the retrospective SCHOLAR-2 study, which showed that the median overall survival (OS) from initiation of the first post-BTK inhibition therapy was 9.7 months (6). Here, BTK is linked to mantle cell lymphoma.